Breast cancer is a heterogeneous disease with substantial variability in relapse rates across clinical and molecular features of the tumor. Clinicopathologic prognostic models (e.g.,Adjuvant!) are widely used to guide therapy. Prognostic gene expression signatures are then used to help clarify treatment options for clinically intermediate risk patients. PAM50 is a validated open source gene expression signature which has recently been endorsed for informing treatment decisions. However, for 40% of breast cancer patients estimated risk, and hence treatment, remains uncertain. Improvement in prognostic models is an active area of research. Models that integrate genomic and clinicopathologic factors show large improvements in prognostic ability. Newer statistical methods (non-linear and time-varying effects, competing risks for comorbid conditions) have improved risk estimates among subgroups and increased accuracy for late relapse (>5 or 10 years after diagnosis). Combination of orthogonal gene expression signatures with microRNA's (miRNA's) promises to increase the proportion of subjects assigned to low and high-risk groups. However, clinical utility of newer models is limited because additional validation in large cohorts with long-term follow-up is needed. Team: We have assembled unique resources to address these issues, including 1,723 well-annotated primary tumor samples from the WHEL cohort of community-dwelling early stage breast cancer survivors. WHEL participants have been actively followed for 15+ years, with regular assessment of comorbidities, body mass index, and physical activity. The team is comprised of leaders in breast cancer treatment and assay development, in genomics, in behavioral research, and in mathematical statistics and prognostic modeling.
We aim to: 1. Assay PAM50, hypoxia gene signatures, and an 18 miRNA panel. Assays will be done at the Genome Institute, Washington Univ., St. Louis. We expect high-quality assays on ~1300 WHEL subjects. 2. Validate the PAM50/hypoxia clinco-genomic signatures, assess potential clinical benefit and identify weaknesses. We will compute risk estimates from published clinicopathologic models (Adjuvant), and genomic (PAM50, hypoxia, miRNA) signatures. We will validate models by comparing predicted and observed survival. Impact: The expected independent validation of the PAM50/hypoxia clinico-genomic signature will help translate its use into the clinic. Improvements for clinically intermediate-risk patientsare anticipated. 3, Develop a new prognostic model accounting for competing comorbidities, nonlinear and time- varying effects, and integrating novel genomic, and clinical factors. New models will integrate clinical and genomic features (i.e., PAM50, hypoxia signatures, miRNAs, comorbidities, obesity) and incorporate statistical refinements such as competing risk from non-cancer mortality and time-varying effects. Impact: We expect to further improve risk estimates for clinically intermediate risk and late relapse groups, and to quantify the expected clinical benefit which might result from these improved models.
Breast cancer is a complex disease, and prognostic models which use clinical data or genomic signatures assayed from the tumor are used by clinicians to predict risk of relapse and aid in treatment decisions. Modifiable lifestyle factors such as physical activity or obesity are known to impact prognosis, but these factors are rarely incorporated into breast cancer survival prediction models. In this project, using a unique cohort of breast cancer patients with archived primary tumor samples, longitudinally collected lifestyle data, and long term follow-up, we propose to validate and compare several existing prognostic tools across a wide spectrum of breast cancer subtypes and to develop an improved prognostic model which integrates clinical, genomic, and lifestyle / psychosocial risk factors such as depression, obesity and physical activity levels.
| Xu, Selene; Thompson, Wesley; Ancoli-Israel, Sonia et al. (2018) Cognition, quality-of-life, and symptom clusters in breast cancer: Using Bayesian networks to elucidate complex relationships. Psychooncology 27:802-809 |
| Hartman, Sheri J; Marinac, Catherine R; Cadmus-Bertram, Lisa et al. (2018) Sedentary Behaviors and Biomarkers Among Breast Cancer Survivors. J Phys Act Health 15:1-6 |
| Proudfoot, James; Faig, Walter; Natarajan, Loki et al. (2018) A joint marginal-conditional model for multivariate longitudinal data. Stat Med 37:813-828 |
| Hartman, Sheri J; Marinac, Catherine R; Bellettiere, John et al. (2017) Objectively measured sedentary behavior and quality of life among survivors of early stage breast cancer. Support Care Cancer 25:2495-2503 |
| de Vries Schultink, A H M; Alexi, X; van Werkhoven, E et al. (2017) An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome. Breast Cancer Res Treat 161:567-574 |
| Marinac, Catherine R; Nelson, Sandahl H; Flatt, Shirley W et al. (2017) Sleep duration and breast cancer prognosis: perspectives from the Women's Healthy Eating and Living Study. Breast Cancer Res Treat 162:581-589 |
| Jankowska, Marta M; Natarajan, Loki; Godbole, Suneeta et al. (2017) Kernel Density Estimation as a Measure of Environmental Exposure Related to Insulin Resistance in Breast Cancer Survivors. Cancer Epidemiol Biomarkers Prev 26:1078-1084 |
| Marinac, Catherine R; Nelson, Sandahl H; Breen, Caitlin I et al. (2016) Prolonged Nightly Fasting and Breast Cancer Prognosis. JAMA Oncol 2:1049-55 |
| Liu, Lin; Messer, Karen; Baron, John A et al. (2016) A prognostic model for advanced colorectal neoplasia recurrence. Cancer Causes Control 27:1175-85 |
| Barbazan, Jorge; Dunkel, Ying; Li, Hongying et al. (2016) Prognostic Impact of Modulators of G proteins in Circulating Tumor Cells from Patients with Metastatic Colorectal Cancer. Sci Rep 6:22112 |
Showing the most recent 10 out of 16 publications
